We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Presents 5-Year Cost Data of CRT Devices
Read MoreHide Full Article
Medical device major Medtronic plc (MDT - Free Report) recently presented an economic analysis of five-year data on cardiac resynchronization therapy (CRT) devices within its Cardiac Rhythm & Heart Failure (CRHF) division. This study was conducted through REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) trial.
The evaluation inferred the fact that implanting CRT devices are cost effective for patients with mild heart failure. Additionally, it stated that these devices if used in early stage treatment should enable the patients to live longer.
CRT is considered to be a standardized treatment, which has proved to make the quality of life better and also reduce hospitalizations. However, despite significant clinical evidence and guideline recommendations in support of CRT, multiple studies have shown the therapy to be underutilized in eligible patients.
Meanwhile, REVERSE happens to be the largest study to assess the long-term clinical impact and survival benefit of devices combining CRT with a defibrillator compared with CRT pacemakers. In fact, it is also the first study to show the cost-effectiveness of CRT when implanted earlier in the diseased state.
Medtronic’s CRHF division claims that CRT has been established long ago as a therapy that significantly improves outcomes for patients with heart failure. Additionally, the REVERSE trial substantiates the economic value of CRT. It offers the hospital systems with valuable inputs in order to make decisions about CRT as a treatment option and the suitable timing of CRT for the cardiac patients. Moving ahead, Medtronic’s goal is primarily to increase value by improving patient outcomes and optimizing costs.
Notably, CRHF, a part of Medtronic’s Cardiac & Vascular Group performed well during the last reported fiscal third quarter. Sales grew 7% year over year on robust performance from Heart Failure franchise. The latest positive data for its CRT devices adds another feather to the successful developments in this sub segment. Very recently the company received CE mark for a suite of quadripolar CRT pacemakers that also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (TSLA - Free Report) machines.
We particularly believe Metronic’s focus to expand its foothold in the global heart failure market is actually strategic, taking into consideration it’s still untapped potential and how fast the market is expanding. As per a GlobalData report, the global heart failure market is set to grow to $11.8 billion by 2025, at a CAGR of 13.7%. Another report of Research and Markets states that the global cardiovascular implants market is set to grow at a CAGR of 4.5% by 2020, with CRT devices being the key driver. Therefore Medtronic can cash in on the future prospects of these markets simultaneously.
Share Price Performance
Medtronic is currently trading above the Zacks categorized Medical - Products industry. This is on the back of recently concluded impressive third-quarter 2017 report. In the majority of last one month the share price trend was trailingbelow the industry trend. Currently the stock increases 8.1% compared with the broader industry’s gain of 6.8%. Furthermore, the company’s fundamentals seem to be strong with a solid 5-year CAGR revenue of 15.5%, which raises confidence in the stock.
Zacks Rank & Key Picks
Medtronic currently has a Zacks Rank #3 (Hold). Better-ranked medical stocks are Glaukos Corp. (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . Glaukos sports a Zacks Rank #1 (Strong Buy), while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of 22.6%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 34.4% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medtronic (MDT) Presents 5-Year Cost Data of CRT Devices
Medical device major Medtronic plc (MDT - Free Report) recently presented an economic analysis of five-year data on cardiac resynchronization therapy (CRT) devices within its Cardiac Rhythm & Heart Failure (CRHF) division. This study was conducted through REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) trial.
The evaluation inferred the fact that implanting CRT devices are cost effective for patients with mild heart failure. Additionally, it stated that these devices if used in early stage treatment should enable the patients to live longer.
CRT is considered to be a standardized treatment, which has proved to make the quality of life better and also reduce hospitalizations. However, despite significant clinical evidence and guideline recommendations in support of CRT, multiple studies have shown the therapy to be underutilized in eligible patients.
Meanwhile, REVERSE happens to be the largest study to assess the long-term clinical impact and survival benefit of devices combining CRT with a defibrillator compared with CRT pacemakers. In fact, it is also the first study to show the cost-effectiveness of CRT when implanted earlier in the diseased state.
Medtronic PLC Price
Medtronic PLC Price | Medtronic PLC Quote
Medtronic’s CRHF division claims that CRT has been established long ago as a therapy that significantly improves outcomes for patients with heart failure. Additionally, the REVERSE trial substantiates the economic value of CRT. It offers the hospital systems with valuable inputs in order to make decisions about CRT as a treatment option and the suitable timing of CRT for the cardiac patients. Moving ahead, Medtronic’s goal is primarily to increase value by improving patient outcomes and optimizing costs.
Notably, CRHF, a part of Medtronic’s Cardiac & Vascular Group performed well during the last reported fiscal third quarter. Sales grew 7% year over year on robust performance from Heart Failure franchise. The latest positive data for its CRT devices adds another feather to the successful developments in this sub segment. Very recently the company received CE mark for a suite of quadripolar CRT pacemakers that also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (TSLA - Free Report) machines.
We particularly believe Metronic’s focus to expand its foothold in the global heart failure market is actually strategic, taking into consideration it’s still untapped potential and how fast the market is expanding. As per a GlobalData report, the global heart failure market is set to grow to $11.8 billion by 2025, at a CAGR of 13.7%. Another report of Research and Markets states that the global cardiovascular implants market is set to grow at a CAGR of 4.5% by 2020, with CRT devices being the key driver. Therefore Medtronic can cash in on the future prospects of these markets simultaneously.
Share Price Performance
Medtronic is currently trading above the Zacks categorized Medical - Products industry. This is on the back of recently concluded impressive third-quarter 2017 report. In the majority of last one month the share price trend was trailingbelow the industry trend. Currently the stock increases 8.1% compared with the broader industry’s gain of 6.8%. Furthermore, the company’s fundamentals seem to be strong with a solid 5-year CAGR revenue of 15.5%, which raises confidence in the stock.
Zacks Rank & Key Picks
Medtronic currently has a Zacks Rank #3 (Hold). Better-ranked medical stocks are Glaukos Corp. (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . Glaukos sports a Zacks Rank #1 (Strong Buy), while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of 22.6%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 34.4% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>